Literature DB >> 34094676

HMGA1 induces EZH2 overexpression in human B-cell lymphomas.

Marco De Martino1, Pedro Nicolau-Neto2, Luis Felipe Ribeiro Pinto2,3, Alexandra Traverse-Glehen4,5, Emmanuel Bachy5,6, Vincenzo Gigantino7, Rossella De Cecio7, Francesco Bertoni8,9, Paolo Chieffi10, Alfredo Fusco1, Francesco Esposito1.   

Abstract

EZH2 is an enzymatic subunit of PRC2, an epigenetic regulator that triggers the methylation of the histone H3 lysine 27 silencing the transcription of several genes. EZH2 has a critical role in cancer progression, since its overexpression has been associated with increased cancer cell invasiveness, drug resistance and poor patient survival. However, the mechanisms accounting for EZH2 overexpression in cancer remain still unclear. Intriguingly, also HMGA protein overexpression is a feature of many human malignancies and correlates with the presence of metastases and a poor outcome. The HMGA proteins, including HMGA1 and HMGA2, belong to the architectural transcription factors that play a key role in the organization of chromatin structure. Here, we report a statistically significant correlation between HMGA1 and EZH2 expression in human lymphomas. We demonstrate that HMGA1 is able to bind EZH2 promoter and induce its activity. Consistently, silencing of HMGA1 expression results in the downregulation of the EZH2 levels leading to a decreased proliferation and migration rate of human lymphoma cell lines. Therefore, these data identify HMGA1 as an EZH2 activator, suggesting a novel molecular mechanism contributing to EZH2 overexpression in human malignancies and a synergism of these proteins in cancer progression. AJCR
Copyright © 2021.

Entities:  

Keywords:  B-cell lymphomas; EZH2; HMGA1

Year:  2021        PMID: 34094676      PMCID: PMC8167683     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  59 in total

1.  Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas.

Authors:  Christopher J Sneeringer; Margaret Porter Scott; Kevin W Kuntz; Sarah K Knutson; Roy M Pollock; Victoria M Richon; Robert A Copeland
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-15       Impact factor: 11.205

2.  High level expression of the HMGI (Y) gene during embryonic development.

Authors:  G Chiappetta; V Avantaggiato; R Visconti; M Fedele; S Battista; F Trapasso; B M Merciai; V Fidanza; V Giancotti; M Santoro; A Simeone; A Fusco
Journal:  Oncogene       Date:  1996-12-05       Impact factor: 9.867

3.  Enhancer of zeste homolog 2 is widely expressed in T-cell neoplasms, is associated with high proliferation rate and correlates with MYC and pSTAT3 expression in a subset of cases.

Authors:  Min Shi; Ali Shahsafaei; Cuiling Liu; Hongbo Yu; David M Dorfman
Journal:  Leuk Lymphoma       Date:  2014-10-30

4.  The high-mobility group A1-estrogen receptor β nuclear interaction is impaired in human testicular seminomas.

Authors:  Francesco Esposito; Francesca Boscia; Vincenzo Gigantino; Mara Tornincasa; Alfredo Fusco; Renato Franco; Paolo Chieffi
Journal:  J Cell Physiol       Date:  2012-12       Impact factor: 6.384

5.  Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation.

Authors:  Boris G Wilson; Xi Wang; Xiaohua Shen; Elizabeth S McKenna; Madeleine E Lemieux; Yoon-Jae Cho; Edward C Koellhoffer; Scott L Pomeroy; Stuart H Orkin; Charles W M Roberts
Journal:  Cancer Cell       Date:  2010-10-19       Impact factor: 31.743

Review 6.  Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer.

Authors:  Bayley A Jones; Sooryanarayana Varambally; Rebecca C Arend
Journal:  Mol Cancer Ther       Date:  2018-03       Impact factor: 6.261

Review 7.  Targeting epigenetic regulators for cancer therapy.

Authors:  Susan Wee; Dash Dhanak; Haitao Li; Scott A Armstrong; Robert A Copeland; Robert Sims; Stephen B Baylin; Xiaole Shirley Liu; Liang Schweizer
Journal:  Ann N Y Acad Sci       Date:  2014-02       Impact factor: 5.691

8.  Thyroid cell transformation requires the expression of the HMGA1 proteins.

Authors:  Maria Teresa Berlingieri; Giovanna M Pierantoni; Vincenzo Giancotti; Massimo Santoro; Alfredo Fusco
Journal:  Oncogene       Date:  2002-05-02       Impact factor: 9.867

9.  The HMG-I oncogene causes highly penetrant, aggressive lymphoid malignancy in transgenic mice and is overexpressed in human leukemia.

Authors:  Yi Xu; Takita Felder Sumter; Raka Bhattacharya; Abeba Tesfaye; Ephraim J Fuchs; Lisa J Wood; David L Huso; Linda M S Resar
Journal:  Cancer Res       Date:  2004-05-15       Impact factor: 12.701

10.  Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.

Authors:  Ryan D Morin; Nathalie A Johnson; Tesa M Severson; Andrew J Mungall; Jianghong An; Rodrigo Goya; Jessica E Paul; Merrill Boyle; Bruce W Woolcock; Florian Kuchenbauer; Damian Yap; R Keith Humphries; Obi L Griffith; Sohrab Shah; Henry Zhu; Michelle Kimbara; Pavel Shashkin; Jean F Charlot; Marianna Tcherpakov; Richard Corbett; Angela Tam; Richard Varhol; Duane Smailus; Michelle Moksa; Yongjun Zhao; Allen Delaney; Hong Qian; Inanc Birol; Jacqueline Schein; Richard Moore; Robert Holt; Doug E Horsman; Joseph M Connors; Steven Jones; Samuel Aparicio; Martin Hirst; Randy D Gascoyne; Marco A Marra
Journal:  Nat Genet       Date:  2010-01-17       Impact factor: 38.330

View more
  3 in total

Review 1.  High Mobility Group A1 (HMGA1): Structure, Biological Function, and Therapeutic Potential.

Authors:  Lu Wang; Ji Zhang; Min Xia; Chang Liu; Xuyu Zu; Jing Zhong
Journal:  Int J Biol Sci       Date:  2022-07-04       Impact factor: 10.750

2.  The role of HMGA1 protein in gastroenteropancreatic neuroendocrine tumors.

Authors:  Marco De Martino; Simona Pellecchia; Francesco Esposito; Nadia Tosti; Cristina Quintavalle; Serenella Eppenberger-Castori; Vincenza Carafa; Alberto Righi; Paolo Chieffi; Alfredo Fusco; Luigi Maria Terracciano; Pierlorenzo Pallante
Journal:  Cell Cycle       Date:  2022-03-14       Impact factor: 5.173

Review 3.  Critical role of the high mobility group A proteins in hematological malignancies.

Authors:  Marco De Martino; Francesco Esposito; Alfredo Fusco
Journal:  Hematol Oncol       Date:  2021-10-12       Impact factor: 4.850

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.